Sensei biotherapeutics to present new preclinical data for sns-101, a proprietary anti-vista antibody, at the 36th annual meeting of the society for immunotherapy of cancer (sitc)

Boston, oct. 01, 2021 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it will present preclinical data for its anti-vista (v-domain ig suppressor of t cell activation) product candidate, sns-101, during the 36th annual meeting of the society for immunotherapy of cancer (sitc) being held in washington, d.c. from november 10 - 14, 2021. these data are the first preclinical data to be presented by sensei bio in a scientific forum from the company's tmab (tumor microenvironment activated biologics) platform.
SNSE Ratings Summary
SNSE Quant Ranking